Showing posts with label Medical Scam. Show all posts
Showing posts with label Medical Scam. Show all posts

Thursday, June 20, 2013

यूरोपियन कमिशन ने रैनबैक्सी पर 10.3 मिलियन यूरो का जुर्माना लगाया


नई दिल्ली।। यूरोपीय यूनियन ऐंटि ट्रस्ट कमिशन ने रैनबैक्सी लैब्स पर 10.3 मिलियन यूरो (80 करोड़ से ज्यादा) का जुर्माना लगाया है। यह जुर्माना ऐंटि डिप्रेशन दवा के जेनेरिक वर्जन को लॉन्च किए जाने में देरी करने पर लगाया गया है। रैनबैक्सी का कहना है कि वह इसके खिलाफ अदालत में अपील दायर करेगी। कमिशन ने यूरोपीय मार्केट में ऐंटि डिप्रेशन दवा साइट्लोप्रैम के जेनेरिक वर्जन का लॉन्च टालने के मामले में रैनबैक्सी लैब्स और डेनमार्क की कंपनी लुंडबेक सहित कई जेनेरिक कंपनियों पर जुर्माना लगाया है।

कंपनी के प्रवक्ता ने बताया, 'रैनबैक्सी यूरोपीय कमिशन के फैसले से निराश है। वह इसके खिलाफ यूरोपीय यूनियन के जनरल कोर्ट में अपील दायर करेगी। ये घटनाएं 10 साल पहले हुई थीं। कंपनी का मानना है कि कमिशन ने तथ्यों को गलत तरीके से समझा और कानून का गलत इस्तेमाल किया।'

यूरोपीय यूनियन कॉम्पिटिशन संस्था ने डेनमार्क की फार्मास्युटिकल कंपनी पर 93. 8 मिलियन यूरो और रैनबैक्सी सहित सभी जेनेरिक फर्मों पर 52.2 मिलियन यूरो की पेनल्टी लगाई है। बाकी जेनेरिक फर्मों में अलफार्मा (अब जोएटिस), मर्ककेजीएए/जेनेरिक्स यूके (जेनेरिक्स यूके अब मायलान का हिस्सा है) और ऐरो (अब यह एक्टाविस का हिस्सा है) शामिल हैं। डेनमार्क की फार्मा कंपनी ने 2002 में जेनेरिक फर्मों के साथ ये समझौते किए थे। यूरोपीय यूनिट ऐंटि ट्रस्ट कमिशन के मुताबिक, इन समझौते से यूरोपीय यूनियन के ऐंटि ट्रस्ट नियमों का उल्लंघन हुआ है।

कमिशन के वाइस प्रेजिडेंट और कॉम्पिटिशन पॉलिसी के इंचार्ज जे अलम्यूनिया ने बताया, 'यह बात स्वीकार नहीं की जा सकती कि कोई कंपनी अपने कॉम्पिटिटर्स को बाजार में घुसने से रोकने के लिए पैसे देकर सस्ती दवाओं की एंट्री में देरी करे। इस तरह के समझौतों से सीधा मरीजों और नैशनल हेल्थ सिस्टम को नुकसान पहुंचता है। कमिशन इस तरह की ऐंटि-कॉम्पिटिटिव हरकतों को बर्दाश्त नहीं करेगा।

कमिशन ने जुलाई 2012 में शुरुआती जांच में कहा था कि लुंडबेक और रैनबैक्सी सहित बाकी जेनेरिक फर्मों के साथ सेटलमेंट अग्रीमेंट का मकसद सस्ती जेनेरिक दवाओं की बाजार में एंट्री को रोकना था, जो यूरोपीय यूनिट ऐंटि ट्रस्ट नियमों का उल्लंघन है। यूरोपीय यूनियन कॉम्पिटिशन वॉचडॉग ने जुलाई की जांच में पाया था कि डेनमार्क की कंपनी की दवा साइट्लोप्रैम की पेटेंट एक्सपायरी के बाद इस कंपनी ने चार जेनेरिक फर्मों को इस दवा के सस्ते वर्जन का लॉन्च टालने के लिए पैसे दिए।

कमिशन के बयान में कहा गया है, 'अनुभव बताते हैं कि जेनेरिक कॉम्पिटिशन से दवाओं की कीमत में भारी गिरावट होती है। इससे ब्रैंडेड कंपनी के प्रॉफिट में जबरदस्त कमी आती है, जबकि मरीजों को फायदा होता है।'
साभार:
ईटी ब्यूरो, इकनॉमिक टाइम्स | Jun 20, 2013, 09.00AM IST
http://navbharattimes.indiatimes.com/business/business-news/european-commission-slaps-rs-80-cr-fine-on-ranbaxy/businessarticleshow/20670367.cms

Monday, February 4, 2013

Jeevandai Aarogya Yojana Scam: SWINDLED OF 2.5L : Doctors ‘dupe’ cancer patient

Mumbai: A cancer patient, Matunga resident Rajesh Singh (32), has alleged that he was duped of Rs 2.5 lakh by a Byculla-based private hospital. Singh, said two doctors from the hospital charged him for treatment as well as pocketed the money claimed under the Jeevandai Aarogya Yojana scheme.

Singh approached the J J Marg police station and the Economic Offences Wing (EOW) on Wednesday, alleging that the doctors not only drained him financially, but were also negligent in the treatment. For a second opinion, Singh had approached one of the doctors, who convinced the victim to undergo treatment at the Byculla hospital instead of renowned cancer centres.

Singh said he was asked to deposit Rs 2.5 lakh in installments, but was never given receipts. Singh’s family accidentally got access to some papers from the blood bank mentioning the government scheme.

“On inquiring, we found out that Rs 1.5 lakh had been paid to the hospital under the scheme for my brother’s treatment. The government record showed the patient’s address as Malegaon,” said Singh’s sister Sangeeta, adding that a social worker attached to the hospital had collected the cheque and encashed it.

Senior PI S Surve said, “An inquiry is on.” The EOW too is collecting details. Head of Directorate of Health Services Dr Archana Patil said she will look into the matter.
Courtesy:
S Ahmed Ali & Sumitra Deb Roy TNN
http://epaper.timesofindia.com/Default/Scripting/ArticleWin.asp?From=Archive&Source=Page&Skin=TOINEW&BaseHref=TOIM/2013/01/31&PageLabel=9&EntityId=Ar00902&ViewMode=HTML

Sunday, February 3, 2013

MEDICAL SCAM: Appoint spl officer to probe charges against implant firm: FDA

Mumbai: A week after the Bombay HC declined to quash the FIR against DePuy Medical Private Limited, a group company of Johnson & Johnson, FDA commissioner Mahesh Zagde has urged police commissioner Satya Pal Singh to appoint a special investigating officer to probe the charges against the firm.

“The HC has made it clear that the probe against the firm shall continue. The firm has implanted faulty medical devices. In USA and Europe, it has not only withdrawn the product, but also compensated the patients who had undergone surgery with faulty devices. In India, it has ignored most aggrieved patients. In view of seriousness of the case and also in larger public interest, a special investigation officer should be appointed,” Zagde said.

In a letter to Singh, Zagde pointed out that after it was confirmed that faulty devices had been implanted, it was the firm’s responsibility to recall the product, identify aggrieved patients and take necessary measures for a revision surgery. “Our information is that while 60% patients needed revision surgeries, no steps were taken to identify the patients. Under such circumstances, FDA can’t be a silent spectator. We stepped in and initiated criminal proceedings,” he said.

Further, Zagde said the firm has admitted that the devices were faulty and that it had recalled defective products across the world, but in India, it did not take adequate care to protect the safety of the patients. The firm has denied the charges, saying the FIR was an abuse of process of law and has resulted in a serious miscarriage of justice.
Courtesy:
Prafulla Marpakwar TNN
http://epaper.timesofindia.com/Default/Scripting/ArticleWin.asp?From=Archive&Source=Page&Skin=TOINEW&BaseHref=TOIM/2013/01/31&PageLabel=9&EntityId=Ar00901&ViewMode=HTML

Tuesday, January 8, 2013

Medical Scam : Prices double as private vaccines flood market

NEW DELHI: The Universal Immunisation Programme (UIP) seems to have slipped almost entirely into the grip of the private sector as the government's vaccine institutes that were reopened in February 2010 after being shut down two years ago are yet to contribute in any significant way. In the process, the cost of most vaccines has more than doubled since 2006-07.

Barring oral polio vaccine, the cost of other routine vaccines that added up to a little over a quarter of the annual routine immunization budget has increased to account for more than 50% of the entire budget, shows the response to an RTI application filed with the Vaccine Procurement Cell in the health ministry by Dr K V Babu, central council member of the Indian Medical Association.

In 2006-07, over 90% of the DPT (diphtheria, pertussis, tetanus) vaccine doses and over 80% of the tetanus toxoid vaccine used for UIP were supplied by the Pasteur Institute of India (PII) in Coonoor and the Central Research Institute (CRI) in Kasauli. In 2012-13, the two institutes together barely produced 36% of the DPT vaccines used and 23% of the TT vaccine used for the UIP.

The price of DPT vaccine has more than doubled between 2006-07 and 2012, going up from Rs 12 to Rs 28 per vial of ten doses. Similarly, the price of TT vaccine has gone up from Rs 6 to Rs 15.

The BCG Vaccine Laboratory in Guindy, Chennai was the sole supplier of BCG vaccine for the UIP. The government is now entirely dependent on the private sector as no other government institute produces BCG vaccine. The two other manufacturers of BCG vaccine, Serum Institute of India (SII) in Pune and Green Signal Bio-Pharma Ltd in Chennia, are private companies. Since 2008, the price of BCG has gone up from Rs 13 to Rs 30 per vial of ten doses.

Interestingly, the least increase in cost has been in the case of measles, where prices have risen by less than 25% despite the demand for doses in 2012-13 being five times what it was in 2006-07. Perhaps it is no coincidence that the measles vaccine was the one that already had a private monopoly even in 2006-07.

The three government institutes, which produced the bulk of the vaccines required for the basic immunisation programme against six diseases, were shut down in 2008 reportedly for not being compliant with good manufacturing practices (GMP) by then health minister Anbumani Ramadoss. This move was sharply criticised by the parliamentary standing committee on health and family welfare which observed that it was the government's responsibility to invest in its own institutes to ensure they were GMP complaint instead of using that as an excuse to shut them down leaving the UIP at the mercy of the private sector.

Though all three institutes were reopened in February 2010, so far, the BCG Vaccine Laboratory has not produced a single dose of vaccine for the immunisation programme and PII Coonoor and CRI Kasauli have been producing a fraction of what they used to supply earlier.

The two other vaccines in the basic UIP are OPV and measles vaccine. For the measles vaccine, the RTI reply of the vaccine procurement unit of the ministry lists only one supplier, the Serum Institute of India in Pune, though the Central Bureau of Health Intelligence (CBHI) lists Indian Immunological Ltd and Human Biologicals Institute, two government units, as suppliers too. However, they do not seem to produce any significant amount. A measles vaccine dose currently costs the government over Rs 10.

In the case of OPV vaccine, the biggest suppliers seem to be two private companies Panacea Biotech Ltd and Bharat Biotech International Ltd in Hyderabad, which seem to meet the bulk of the demand. Though BIBCOl Bulandshahr, a government institute, and Haffkine Biopharmaceutical Ltd in Mumbai, a public sector unit (PSU), are listed as producers of OPV, their contribution seems negligible, going by the data of the CBHI.

The government units which made an insignificant contribution to the UIP were not chosen for being closed down. It is the units which contributed to a large share of the immunisation programme's demand that were shut down, resulting in the entire market for the vaccines produced by these units being turned over to the private companies.
Courtesy: 
By Rema Nagarajan, TNN | Jan 6, 2013, 05.52 AM IST
http://timesofindia.indiatimes.com/india/Prices-double-as-private-vaccines-flood-market/articleshow/17907688.cms

Saturday, December 29, 2012

Medical Scam: With no laws, pharma firms have a field day

IN THE absence of any penal provisions that may be applied in cases where pharmaceutical majors use unethical practices to woo doctors to promote drugs, pharma companies brazenly offer incentives to doctors, flouting the Department of Pharmaceuticals’ ‘voluntary code’.

As a result, while a December 2009 code of medical ethics developed by the Medical Council of India (MCI) includes legal provisions to punish doctors who accept gifts from pharmaceutical companies in return for aggressively prescribing certain drugs, there is nothing to stop drug manufacturers’ unethical practices.

Santhosh M R of the Centre for Trade and Development (CENTAD), an organisation that conducted a study on pharmaceutical companies on behalf of the Competition Commission of India (CCI), says, “In the absence of any legal provision, no company can be prosecuted (for such activities). Thus, they are fearless.” On Thursday, DNA reported that the country’s top pharma firms routinely offer considerations ranging from gifts including electronics and gold coins to foreign trips to doctors who achieve pre-fixed targets for prescriptions of certain drugs.

The 58th report of the Parliamentary Standing Committee on Health and Family Welfare dated May 8, 2012 says there appears to be little logic in keeping the code for companies a voluntary one. “The Committee has been given to understand that the voluntary code has generally not been successful in curbing unethical practices and off-label promotion of drugs,” the report says, adding that the Secretary (Pharmaceuticals) was unable to offer any valid reason for not making the uniform code a statutory provision.

A statement to DNA from the World Health Organization also opined that implementation of the code must be reviewed. “If it is found that it has not been voluntarily and effectively implemented by pharmaceutical associations/ companies, the government should consider making it a statutory or binding regulation,” the WHO said.

Also worrying is that companies keep the working and service conditions of medical representatives, the foot soldiers who meet doctors and promote drugs, highly suspect.

While the Sales Promotion Employee (Conditions and Services) Act, 1976 empowers medical representatives and regulates their service conditions, the Federation of Medical & Sales Representatives’ Association of India (FMRAI) which represents more than 1.5 lakh medical representatives, says almost no pharma firm issues legally amended appointment letters as stipulated by the Act. “If they give appointments under Form A, they would be bound by the Act and all the labour laws would prevail. In such a scenario, the employees will have a stronger say and can refuse to participate in unethical practices,” said JS Majumdar, former general secretary of the association.

“This in turn would mean that they would be forced to undertake unethical practices.Even if they are caught, the blame would come on representatives and doctors,” Santhosh added.

Several appointment letters of sales promotion employees accessed by DNA show that they are recruited as territory business managers, product executive and product specialists, etc. In fact, when the issue was brought to the notice of the central government in August 2010, KM Gupta, economic advisor to the Centre’s labour department, sent a letter to labour secretaries of all states advising imprisonment as a penalty for employers who violate the provisions of the Act.

The FMRAI also gave a memorandum to the Labour Minister, Government of Mahrashtra, in February 2012 regarding the violation of the law by pharma companies.
Courtesy:
Sandeep Pai l Mumbai
Published Date:  Dec 28, 2012
http://epaper.dnaindia.com/story.aspx?id=35299&boxid=13525&ed_date=2012-12-28&ed_code=820009&ed_page=10

Medical Scam: ‘Pharma firms-doctors nexus puts patients at risk’

Responding to reports in DNA about unethical practices adopted by pharmaceutical companies to incentivise doctors to promote certain drugs, medical practitioners agreed that the long-term repercussions of such brazen wooing of doctors with gifts and foreign trips could be serious.

“Due to incentives, some doctors start over-prescribing to achieve the targets and the stockist goes out of his way to sell the products. This ultimately affects the customers in terms of high costs and overdosing,” said Dr Suchitra Ramkumar, a medical practitioner and trustee of Citizen Consumer and Civic Action Group (CAG).
Apart from the fact that doctors’ overzealousness in prescribing drugs could see rising healthcare costs, there is also the issue of medical side-effects. “Over-prescribing may lead to patients going through various physical problems due to side–effects,”said Dr Satyajit Kr Singh MS, Fellowship of the Royal College of Surgeons(FRCS) and Ex. Lecturer of the Diplomate Institute of Urology (London), who has worked in various countries across the world.

Admitting that the practice of accepting gifts does exist among doctors across the country, Dr BS Garg, president of the Maharashtra Voluntary Heath Association of India (VHAI) working in Wardha, said, “In districts, the doctors and chemists are even more closely interlinked and so by offering incentives to them, the companies are trying to capture the market. All the money which a pharma company invests in buying gifts or offering incentives is ultimately recovered from the customer.”


The World Health Organistaion in a statement to DNA said the uniqueness of the Indian healthcare system is its relatively well-established private healthcare system. “This means that all decisions with regard to patient care are made by individual or a group of doctors, making doctors very important as a client to pharmaceutical companies. Understanding the MCI Code is only part of the compliance programme for pharmaceutical companies. From a more practical perspective, companies need be aware that anti-corruption compliance is not an additional value to risk management, but an indispensable part of the whole corporate business,” the statement said.

Dean of the Lokmanya Tilak Municipal General Hospital, Sion, one of Mumbai’s largest civic government-run hospitals, Dr SuleimanMerchant, said there would be no takers if there were no givers. “So if there are strict laws in the country for the gift takers, there should be equally strict laws for Pharma companies too,” he said, mirrorring the opinion of several experts. “Not all are involved in this unethical practice,” he added.

According to the President of the Indian Medical Association (Maharashtra) DrAnil Pachnekar also agreed that doctors often face the repercussions while companies offering these gifts get away. “Pharma companies target doctors with more prescriptive power, be it in cities or smaller towns. The ones who are caught are dealt out punishment, but the pharma companies are left out. The crackdown is only on doctors and companies get away because they have a strong lobby.”
Courtesy:
Sandeep Pai l Mumbai
Published Date:  Dec 29, 2012
http://epaper.dnaindia.com/story.aspx?id=35391&boxid=15333&ed_date=2012-12-29&ed_code=820009&ed_page=9

Sunday, December 16, 2012

Medical Scam : Profit: The heart of the problem

A lack of knowledge and the urgency to get cardiac problems treated immediately makes many patients and their families opt for expensive procedures without considering the varied and often blown-up charges that private hospitals bill them for,

When Dombivli resident Meera Joshi was given a cost estimate of Rs3.5 lakh for her 54-year old mother’s angioplasty at a hospital in Mulund two months ago, she had no option but to sign on the contract handed to her.

Coronary angiography is a procedure that detects blockage in the arteries of the heart. It is a day care procedure where the patient needs to be admitted to the hospital. The procedure involves puncturing the artery from the hand or the groin and inserting a tube with a camera that goes to the heart. A dye is used to contrast images and detect the blockages in the heart.

“My mother had two major blocks. The doctors told us that if she did not undergo an angioplasty, she could suffer a heart attack in the next few hours. We were told the estimated cost and had no option. We paid Rs1.5 lakh up front,” said Joshi, whose name has been changed on request.

Increasingly, patients admitted to hospitals for serious ailments such as heart diseases feel cheated by hospitals. In Joshi’s case, she found this out after she enquired with relatives who were doctors and consultants. She found out that a reasonable estimate for an angioplasty is about Rs2.5 lakh. After the procedure, she negotiated with the hospital authorities and eventually paid about Rs 2.8 lakh, less than what she had been initially asked to pay but more than the actual cost at other hospitals.

Experts say that patients have no clue what they are paying for as few hospitals explain to patients the components of the bill. In case of angioplasty, the cost of the stents, which itself can cost anywhere between Rs80,000 to Rs1.35 lakh, forms the biggest component of the bill. In case of a bypass surgery, the cost of the consumables is a lot less (about Rs 60,000-Rs 70,000) apart from the charges of the surgeon and the other technical team. This procedure usually costs about Rs2 lakh in a reasonably priced hospital.

“Hospitals do not tell patients the cost of stents, let alone the separate costs of rooms and doctor’s charges. They do not even write down the name of the company whose stent was used on the patient. The patient is always kept in the dark,” said Dr Akash Rajpal, managing director of Ekohealth Management.

In a government hospital, for instance, the transaction is very clear (see interview). “The price of stents is fixed as per the rate contract made by the Directorate of Medical Education. For an Indianmake, the price of the stent is Rs40,000, a European-make costs Rs50,000 and a US-made stent costs Rs65,000,” said Dr Ajay Chaurasia, head of cardiology, BYL Nair Hospital at Mumbai Central.

Consumer court lawyers said that the law requires hospitals to give a detailed bill with a breakup of surgery costs. “In the final bill, hospitals are duty bound to give complete details of the costs including the surgeon or the cardiologist’s quote, the stent’s price including the manufacturer and the guarantee of the stent. When there is a foreign body in a person’s heart, and something goes wrong, the patient should be able to trace the manufacturer,” said Anand Patwardhan, leading consumer court lawyer.

Joshi, for instance, had a bone to pick with the hospital because it had charged twice for usage of Cathlab for angiography (to detect blocks) and angioplasty (to place stents), which was done at the same time in the same operating room.

“Doctors cannot charge different rates for patients in different types of rooms. Similarly, for a procedure on the same table, the hospital can charge for the consumables but not double for the room,” said Patwardhan.

HOSPITALS AREN’T HOTELS — THEY SHOULDN’T TRY TO MAKE MONEY

Dr Bansal is the head of cardiology at JJ hospital, Byculla.

What are the costs involved for someone to get an angioplasty done at JJ hospital? 
Our prices are much lower than prices quoted by the private hospitals. We charge our patients Rs65,000 for a foreign-made stent manufactured by one of the global leaders for stents, which could cost about Rs1 lakh to Rs1.25 lakh in the any of the hospitals outside as per the maximum retail price (MRP).

How does a government hospital manage to bring down prices by so much? 
We bring down the MRP by way of tenders for all drug-eluting stents. Our government agencies negotiate and bring the price down to an extent. We do not seek a profit of even one paisa beyond the final cost we have negotiated. Also, companies keep in mind that our students watch their products being used. This can easily be done in other private hospitals too. Patients are usually confused about what stent is used by the doctor at private hospitals. Patients complain that the system is not transparent enough In our hospital, we hand over the empty containers of the stents with the stickers and everything that comes with it to the patient after the procedure is done. If anyone has a doubt about anything that happened during the procedure, it can be immediately be verified by them, very easily.

What do you think about the pricing of stents at private hospitals? 
Private hospitals negotiate the price for stents, but do not pass on the savings made during the negotiation to patients. A hospital should consider that they are not profit-making organisations and should give their patients a fair deal. There has to be a difference between a hospital and a hotel. Companies also can reduce the charges, considering these are life-saving devices. Both parties should be reasonable about their profit, and not keep it so high.

Stents sold at up to 400% of cost: FDA report
MUMBAI: A study by the state Food and Drugs Administration (FDA) last year said there is a massive disparity between the import price of cardiac implants and their eventual maximum retail price (MRP).

The profit made by the manufacturing company, distributers and hospitals could vary between 100% and 400%, the report said.

The agency had studied the pricing of various imported implants including cardiac stents, heart valves, and pacemakers among others. Tracing the price of the device back to the import price and the distributers’ profit, the pricing of the devices was studied across two to three hospitals in Mumbai.

The report, which was sent to the Central Drug Standard Control Organisation in August last year, stated that the MRP is arbitrarily fixed by the manufacturer without regard for general principals of the Drug Price Control Order (DPCO). This system, according to the report, has been devised for the intermediaries (at least five in each case), involved in the supply chain.

For instance, the import price of a drug-eluting stent was Rs40,710, which is sold at an MRP of Rs 1.5 lakhs.

“When we have technology by way of the Internet to facilitate a direct purchase of the device by the manufacturer or the importer, why does our system have so many intermediaries?” said Sanjay Kale, assistant commissioner, drugs at FDA with an additional charge of intelligence.

The DPCO stipulates that the price of such devices should not exceed 50% of the import price. “We have recommended that margins of the manufacturers and intermediaries be capped,” said Kale.

The report states, “This [the cost] causes burden on the patient and they are left at the mercy of the hospital,” and adds that the price of the implant is negotiated by the hospital and the importer without consulting the patient.

AN EXPENSIVE OPTION
An FDA study last year estimated that profit margins in imported stents could range between 100 and 400%, depending on the hospital where the treatment is being sought.

FDA OBSERVATIONS ON THE PRICING OF SUCH STENTS
The MRP is fixed by the importing company for the benefit of intermediaries.

The selling price of the stent differs from hospital to hospital on a case-to-case basis

A major share of the profit is borne by the importer company. Imported stents are preferred to Indian ones

The price of the stent varies from distributer to distributer even if the importer is the same The interventional cardiologist decides which stent to use.

TWO TYPES OF STENTS

1 A bare-metal stent is a vascular stent without a coating. It is a meshlike tube of thin wire. 2 Drug-eluting stents have three parts. Stent platform, coating, and drug. The stent itself is an expandable metal alloy framework. They have mesh-like designs to allow for expansion, flexibility and ability to make/enlarge openings for side vessels.

RECOMMENDATIONS MADE BY THE FDA
The price of medical devices should be fixed based on the principles of Drug Price Control Order — a government mechanism that regulates the price of drugs in the country.

The price should not exceed 50% of the import price plus cost of importing it.

Efforts should be made to reduce intermediaries in the supply of these devices

CUT SOME COSTS
CONSIDER USING AN INDIAN-MADE STENT

In case of an angioplasty, a patient can opt for a stent manufactured in India that costs between Rs60,000 to Rs80,000. Dr Akshay Mehta, interventional cardiologist, Nanavati Hospital said, “We have not had any adverse results with Indian stents so far. Many of them are approved in the European market. Some of the stent companies also give a warranty and offer a discount if there is a re-blockage in the vessel,” said

KNOW YOUR PRICE
Before you opt for the procedure or pay the bill, compare prices of the procedure at different hospitals. Some agencies can help patients understand the approximate prices charged by various hospitals to improve negotiation.

Opt for a hospital with lower bed costs, operation theatre charges and ICU charges.

Opting for a twin-sharing or a private room increases the cost of the other procedures and doctor’s charges.

OPT FOR SURGERY RATHER THAN AN ANGIOPLASTY
To reduce costs, you could also opt for a bypass surgery, especially in case of multiple blockages. “With stents, there is a five to 10% chance that the block can recur. It is not always very cost effective. Also, if the patient has two blocks in the heart, the cost of surgery will not increase. The cost of angioplasty would double if two stents are placed,” said Dr Suresh Joshi, consultant cardiac surgeon, Jaslok Hospital.

Courtesy:
10 Dec 2012, Hindustan Times (Mumbai), Menaka Rao and Priyanka Vora
http://paper.hindustantimes.com/epaper/viewer.aspx